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e 2, 2013.he aim of this study was to investigate whether the combination of conventional pulmonary vein isolation (PVI) by
circumferential antral ablation with ganglionated plexi (GP) modiﬁcation in a single ablation procedure, yields higher
success rates than PVI or GP ablation alone, in patients with paroxysmal atrial ﬁbrillation (PAF).Background Conventional PVI transects the major left atrial GP, and it is possible that autonomic denervation by inadvertent GP
ablation plays a central role in the efﬁcacy of PVI.Methods A total of 242 patients with symptomatic PAF were recruited and randomized as follows: 1) circumferential PVI
(n ¼ 78); 2) anatomic ablation of the main left atrial GP (n ¼ 82); or 3) circumferential PVI followed by anatomic
ablation of the main left atrial GP (n ¼ 82). The primary endpoint was freedom from atrial ﬁbrillation (AF) or other
sustained atrial tachycardia (AT), veriﬁed by monthly visits, ambulatory electrocardiographic monitoring, and
implantable loop recorders, during a 2-year follow-up period.Results Freedom from AF or AT was achieved in 44 (56%), 39 (48%), and 61 (74%) patients in the PVI, GP, and PVIþGP
groups, respectively (p ¼ 0.004 by log-rank test). PVIþGP ablation strategy compared with PVI alone yielded
a hazard ratio of 0.53 (95% conﬁdence interval: 0.31 to 0.91; p ¼ 0.022) for recurrence of AF or AT. Fluoroscopy
duration was 16  3 min, 20  5 min, and 23  5 min for PVI, GP, and PVIþGP groups, respectively (p < 0.001).
Post-ablation atrial ﬂutter did not differ between groups: 5.1% in PVI, 4.9% in GP, and 6.1% in PVIþGP. No serious
adverse procedure-related events were encountered.Conclusions Addition of GP ablation to PVI confers a signiﬁcantly higher success rate compared with either PVI or GP alone in
patients with PAF. (Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation [AF]; NCT00671905)
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3; revised manuscript received May 27, 2013,proposed as a critical element in the therapeutic effect of
PVI in patients with atrial ﬁbrillation (AF) (1–3). Although
GP ablation alone has produced inconsistent clinical results
in paroxysmal AF (PAF) (4–9), addition of GP ablation to
PVI has increased AF-free survival in both catheter (endo-
cardial approach) (7,10–12) and minimally invasive surgical
ablation (epicardial approach) (13–16). Currently, PVI is the
most widely used ablation approach to treat PAF. WithSee page 2326a 5-year success rate of <30% after a single procedure (17),
and <40% off antiarrhythmic drugs (18), PVI alone is
clearly not sufﬁcient to maintain sinus rhythm.
Abbreviations
and Acronyms
AF = atrial ﬁbrillation
AT = atrial tachycardia
CI = conﬁdence interval
GP = ganglionated plexi
HFS = high-frequency
stimulation
ILR = implantable loop
recorder
PAF = paroxysmal atrial
ﬁbrillation
PV = pulmonary vein
PVI = pulmonary vein
isolation
RF = radiofrequency
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2319In the context of our autonomic denervation project, we
previously conducted the only randomized trial that has
compared the efﬁcacy of PVI with that of PVI with add-
itional GP ablation in patients with PAF (11). The addition
of GP ablation resulted in improved outcome (83.5% vs.
60.6% AF freedom at 1 year with approximately 20% of
patients having undergone a repeat procedure). However,
this pilot study was relatively small (67 patients were
included), and followed patients only as long as 12 months.
In addition, the safety proﬁle of the ablation catheter used
for that study (Ablation Frontiers, Medtronic, St. Paul,
Minnesota) was later questioned (19). Moreover, our
previous trial did not evaluate the comparative efﬁcacy of GP
ablation alone, that is, therefore, not known.
Because conventional PVI transects 3 of the 4 major atrial
GP as well as the ligament of Marshall, it is possible that
autonomic denervation by GP ablation plays a central role in
the efﬁcacy of PVI. The present study was designed to
answer the following questions: 1) Is GP ablation alone as
effective as PVI? 2) Does the addition of GP ablation to PVI
increase the success rate of AF ablation in patients with PAF
without an increase in the procedural risks and complication
rates?Figure 1 Anatomic Location of the 4 GPs
Schematic posterior view of the left and right atria. The 5 major left atrial auto-
nomic GP and axons (superior left GP, inferior left GP, anterior right GP, inferior
right GP, and ligament of Marshall) are shown in yellow, whereas the coronary
sinus and the vein and ligament of Marshall are shown in blue, which travels from
the coronary sinus to the region between the left superior PV and the left atrial
appendage. GP ¼ ganglionated plexi; IVC ¼ inferior vena cava; LIPV ¼ left inferior
pulmonary vein; LSPV ¼ left superior pulmonary vein; RIPV ¼ right inferior
pulmonary vein; RSPV ¼ right superior pulmonary vein. Reprinted with permission
from Calkins et al. (21).Methods
This study was a 2-center randomized trial that took place at
the Department of Cardiology, Athens Euroclinic, Athens,
Greece, and the Arrhythmia Department, State Research
Institute of Circulation Pathology, Novosibirsk, Russia. The
study protocol was approved by the Institutional Ethics
Committee at both centers, and was conducted in compli-
ance with the protocol and in accordance with standard
institutional operating procedures. Patients who met all the
inclusion criteria and were willing to participate were
enrolled, and randomized after providing written informed
consent. The trial was registered at ClinicalTrials.gov
(NCT00671905).
Study patients. Patients were recruited and ablation proce-
dures were performed from June 2009 to December 2010.
Patients were included in the study if they were 18 to 75 years
of age with symptomatic PAF, and left atrial size<50mm (as
obtained from transthoracic echocardiography). Exclusion
criteria were left ventricular ejection fraction <35%, malig-
nancies, serious comorbidity, and history of ablation proce-
dures to treat atrial tachyarrhythmias.
Procedures. Participants were randomized to 1 of the
following 3 groups.
Group 1. CIRCUMFERENTIAL PVI. Patients underwent
conventional PVI by circumferential antral ablation acc-
ording to standard procedures. Circumferential ablation
around the antra of the PV was accomplished with the aid of
electroanatomic mapping (Carto, Biosense Webster Inc.,
Diamond Bar, California) at a distance w2 cm from the
ostia of the left and right PVs (Fig. 1), aimed at a reductionof the voltage of the local elec-
trogram by >80% or a peak-to-
peak bipolar electrogram<0.1 mV.
Group 2. ANATOMIC ABLATION
OF THE 4 MAJOR LEFT ATRIAL GP.
Patients underwent speciﬁc
anatomic ablation of the 4 major
left atrial GP (Fig. 1), using the
method initially described by
Katritsis et al. (4), and modiﬁed by
Pokushalov et al. (20). We previ-
ously showed that anatomic GP
ablation (i.e., targeting the areas
where the 4 major atrial GP are
usually located) produces a better
outcome than GP ablation guided
by a positive parasympathetic re-
sponse (hypotension or atrioven-
tricular block) induced by high-frequency stimulation (HFS)
(20). HFS-guided identiﬁcation of the GP, therefore, was
not deemed necessary for successful GP ablation. In brief,
spiral computed tomography was performed for all patients.
After computer processing (CartoMerge, Biosense Webster),
the resulting image of the left atrium was integrated with the
electroanatomic map of the left atrium. Presumed GP clusters
were ablated 1 to 2 cm outside the PV–left atrium junctions at
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2320the following sites: left superolateral area (superior left GP-SLGP),
right superoanterior area (anterior right GP-ARGP), left
inferoposterior area (inferior left GP-ILGP), and right infer-
oposterior area (inferior right GP-IRGP). The crux GP in the
inferoposterior area of the left atrium was not ablated to
minimize the potential of ablation-related proarrhythmia.
According to our protocol, only GP adjacent to the circum-
ferential ablation line that was necessary for PVI were targeted.
A 7.5-F, 3.5-mm irrigated tip catheter (NaviStar Thermo-
Cool, Biosense Webster) delivering radiofrequency (RF)
energy at 46C, 30 to 35 W, 17 ml/min for 40 s (Stockert,
Biosense Webster) was used. The endpoint of GP ablation
procedure was elimination of atrial electrical activity (peak-to-
peak bipolar electrogram <0.1 mV) at the sites where RF
applications were delivered, as well as abolition of any para-
sympathetic effects elicited by RF energy delivery.
Group 3. CIRCUMFERENTIAL PVI FOLLOWED BY ANATOMIC
ABLATION OF THE 4 MAJOR LEFT ATRIAL GP. Patients under-
went PVI followed by anatomic ablation of the 4 major left
atrial GP. Care was taken that the PVI circumferential line as
indicated in Figures 2 and 3 were in continuation with the GP
ablation sites to avoid introducing arrhythmogenic channels.
Thus, during completion of the PVI, extra lesions were
delivered at the anatomic sites of GP as previously described
(4,20). The endpoint of PVI for both groups 1 and 3 was the
veriﬁcation of PVI by demonstration of both entrance and exit
block with the use of a circular mapping catheter.
Study endpoints and procedural complications. The
primary study endpoint with respect to ablation efﬁcacy
was freedom from AF or other sustained (duration >30 s)
atrial tachyarrhythmia after a single procedure. Follow-upFigure 2 Anatomic Ablation of the Superior Left and Anterior Right G
After pulmonary vein isolation, the ablation lesions are expanded to cover the anatomic s
plexi; RAGP = right anterior ganglionated plexi.was conducted according to the Heart Rhythm Society
(HRS)/European Heart Rhythm Association (EHRA)/
European Cardiac Arrhythmia Society (ECAS) 2012
Consensus Statement (21). Patients were prospectively
assessed for recurrence of AF or other atrial arrhythmia. It
has been shown in animals that autonomic reinnervation
occurred 4 weeks after GP ablation (22), and the effects of
autonomic reinnervation on AF progression and recurrence
are not known. Thus, patients underwent monthly clinical
assessment and ambulatory electrocardiographic monitoring
for 2 years, instead of the minimum 1-year period required
by the HRS/EHRA/ECAS statement. All patients were
instructed to maintain personal records with descriptions of
every episode of symptomatic palpitations and, in case of
persistent arrhythmia episodes, to obtain transtelephonic or
direct electrocardiographic documentation of the underlying
rhythm. Patients were encouraged to use transtelephonic
monitoring even when their symptoms were not typical of
recurrent AF. Moreover, 121 patients also received an
implantable loop recorder (ILR), at the operator’s discretion.
A successful outcome during the follow-up period was
deﬁned as the lack of electrocardiographically recorded AF
and no AF or other sustained atrial arrhythmia on an
ambulatory electrocardiography device and subjective
symptomatic improvement after a 3-month blanking period.
We adopted a blanking period, the immediate period post-
ablation during which recurrence of transient atrial ar-
rhythmias were not considered as RF catheter ablation
failure (21). As part of our routine AF ablation protocol, all
patients received beta-blockers (unless contraindicated),
whereas all patients were kept on anticoagulation for at leastP
ite of presumed ganglionated plexi (GP) clusters. LSGP = left superior ganglionated
Figure 3 Anatomic Ablation of the Inferior Left and Right GP
After pulmonary vein isolation, the ablation lesions are expanded to cover the anatomic site of presumed GP clusters. ILGP¼ inferior left ganglionated plexi; IRGP ¼ inferior right
ganglionated plexi.
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23213 months post-ablation. Secondary endpoints included RF
delivery time and ﬂuoroscopy time. Procedure-related
adverse events (including death, myocardial infarction,
cardiac tamponade, and stroke) were also recorded.
Outcome determination was performed by the local site
investigators in each of the 2 contributing centers, whereas
all statistical analyses were performed independently by 2
investigators who were not involved in data collection or
outcome documentation.
Sample size calculation. A study sample of 80 patients in
each group was calculated to detect a 30% difference in
primary endpoint between any groups of comparison at
a statistical power of 80% at a 5% signiﬁcance level.
Randomization protocol. For allocation of the partici-
pants, a computer-generated list of random numbers was
used. Participants were randomly assigned after simple
randomization procedures (computerized random numbers)
to 1 of 3 ablation groups mentioned earlier. Allocation
concealment was safeguarded by ensuring that allocation was
obtained by computer output after the patients had con-
sented. Due to the invasive nature of the procedures, per-
forming physicians were not blinded to the randomization
allocation, whereas outcome assessors during follow-up were
blinded to the intervention group. Random assignment was
performed in a 1:1:1 ratio to 1 of the 3 strategies, stratiﬁed
by study site.
Statistical analysis. Patients and procedural characteristics
were summarized and presented as mean  SD or as ab-
solute values and percentages, as appropriate. Comparisons
of discrete and continuous variables between the 3 groups
were performed by using the Kruskal-Wallis test. The
primary analysis was based on an intention-to-treat analysis
of all randomized patients who underwent each one of theabove ablation strategies. For the primary study endpoint
(freedom from AF or other sustained atrial arrhythmia),
event rates were calculated from the time since the end of the
blanking period (a 3-month blanking period was adopted
since ablation procedure as mentioned earlier). Kaplan-
Meier analysis was used for each group to assess the
percentage of freedom of AF or other atrial arrhythmia at
follow-up, and data were censored at 2 years or when the
endpoint occurred. Event-free curves were compared by the
log-rank test. All analyses were stratiﬁed by study site. For
the primary endpoint, hazard ratios and 95% conﬁdence
intervals (CIs) were estimated with the use of Cox propor-
tional hazards models.
All reported p values were based on 2-sided tests, and
a p value <0.05 was considered signiﬁcant. All statistical
analyses were performed using STATA software, version
12.0 (StataCorp., College Station, Texas).Results
Patient characteristics and treatment assignment. Dur-
ing the 3-year enrollment period, a total of 242 patients were
eligible and randomly assigned to 1 of the 3 ablation strat-
egies (PVI group ¼ 78, GP ablation group ¼ 82, PVIþGP
ablation group ¼ 82) (Table 1). Participants attended clinic
visits at the time of randomization (baseline) and at 1-month
intervals for 2 years. Two-year follow-up was completed for
all enrolled patients, and ablation strategy crossover was not
required for any of the patients.
Table 1 shows baseline and clinical characteristics, medical
history, and therapy across different groups. In summary,
there were 159 men and 83 women, with an age of 56  8.1
and a range of 28 to 77 years. Values of left ventricular









Age, yrs 56  7.6 56  8.2 56  8.5 0.99
Male 53 (68) 49 (60) 57 (70) 0.51
Medical history
Arterial hypertension 63 (81) 63 (77) 58 (71) 0.54
Diabetes 1 (1) 4 (5) 3 (4) 0.92
Thyroid disease 14 (18) 9 (11) 18 (22) 0.47
Antihypertensive drugs
ACE 20 (26) 10 (10) 11 (13) 0.27
ARB 5 (6) 6 (7) 6 (7) 0.99
Beta-blocker 54 (69) 46 (56) 53 (65) 0.34
Calcium-channel blocker 7 (9) 3 (4) 5 (6) 0.84
Diuretics 4 (5) 7 (9) 9 (11) 0.81
Antiarrhythmic drugs*
Class I antiarrhythmic drugs 23 (30) 26 (32) 29 (35) 0.81
Amiodarone 31 (40) 38 (46) 27 (33) 0.33
Sotalol 3 (4) 3 (4) 6 (7) 0.90
LVEF, % 63  6.8 63  6.6 62  8.1 0.61
LA size, cm 4.8  0.7 4.9  0.6 4.8  0.6 0.40
Values mean  SD or n (%). *Before ablation procedure.
ACE ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker; GP ¼ ganglionated plexi; LA ¼ left atrium; LVEF ¼ left
ventricular ejection fraction; PVI ¼ pulmonary vein isolation.
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2322ejection fraction and left atrial size were 63  7.2% and
4.8  0.63 cm, respectively, for the whole study population.
Finally, ILRs were available for 121 patients (39, 41, and
41 patients in PVI, GP, and PVIþGP ablation group,
respectively).
Primary and secondary endpoints. During a 2-year follow-
up period after the ablation procedure, a total of 44 (56%), 39
(48%), and 61 (74%) patients in the PVI, GP, and PVIþGP
ablation groups, respectively, remained in sinus rhythm
(Table 2). The proportion of patients free from AF or any
sustained atrial arrhythmia was signiﬁcantly higher in the
PVIþGP group compared with PVI or GP strategies alone
(p ¼ 0.0036 by log-rank test) (Fig. 4). In the PVIþGP
ablation group, the hazard ratio for the recurrence of AF or
other sustained atrial arrhythmia was 0.53 (95% CI: 0.31 to











Freedom from AF or
other sustained
atrial arrhythmia
44 (56) 39 (48) 61 (74) 0.001
Secondary
Radiofrequency time, min 41  10 46  12 67  18 <0.001
Fluoroscopy time, min 16  3 20  5 23  5 <0.001
Values n (%) or mean  SD. Analyses were stratiﬁed by study site.
AF ¼ atrial ﬁbrillation; other abbreviations as in Table 1.compared with the PVI and GP ablation strategy alone,
respectively. The comparison of GP and PVI ablation did not
yield any statistically signiﬁcant difference (hazard ratio: 1.26;
95% CI: 0.80 to 1.98; p ¼ 0.314). However, as shown in
Figure 4, after the ﬁrst year of follow-up, the GP ablation
strategy was less effective than the PVI strategy alone. Post-
ablation atrial ﬂutter was seen in 13 patients without any
trend for increased risk in a speciﬁc ablation group: 4 patients
in the PVI group (5.1%), 5 patients in the GP ablation group
(4.9%), and 5 patients in the PVIþGP ablation group (6.1%).
When considering only patients with ILRs (n ¼ 121), at
least an episode of AF or other sustained atrial arrhythmia
was detected in 20 of 39 (51%, PVI group), 22 of 41 (53%,
GP ablation group), and 5 of 41 (12%, PVIþGP ablation
group) patients.
For the primary outcome of freedom from AF or other
sustained atrial arrhythmia, there was no signiﬁcant
treatment-by-site interaction (p ¼ 0.197 to 0.572 for the
interaction terms in the 3 pairwise comparisons), and
PVIþGP ablation was the best strategy at both sites.
The duration of RF delivery time was 41  10 min for PVI
and 46  12 min for GP, whereas for the PVIþGP ablation
group, it was 67  18 min (p < 0.001 between-group
comparison). A signiﬁcant difference in ﬂuoroscopy dura-
tion was also recorded across the 3 ablation strategies: dura-
tion of 16 3 min, 20 5 min, and 23 5 min for the PVI,
GP, and PVIþGP ablation groups, respectively (p < 0.001
between-group comparison) (Table 2).
Procedural complications. No death, myocardial infarc-
tion, or stroke was recorded as an ablation-related complica-
tion. There was only 1 case of cardiac tamponade in a patient
Figure 4 Atrial Fibrillation or Other Sustained Atrial Arrhythmia Recurrence Across the 3 Different Ablation Strategies
Kaplan-Meier estimates were used to calculate the 2-year event rates and comparison was performed using the log-rank test stratiﬁed by study site. A 3-month blanking period
after the ablation procedure was adopted. GP ¼ ganglionated plexi; PVI ¼ pulmonary vein isolation.
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2323in the PVI group who was treated with percutaneous peri-
cardial drainage. The patient had an uneventful recovery.Discussion
Our results indicate that addition of anatomic GP ablation
to conventional PVI improves clinical outcome in patients
with PAF. Notably, the success rate of GP ablation alone
was not signiﬁcantly different from that of conventional
PVI; the lesion sets of both approaches have signiﬁcant
overlap, but the latter covers a substantially larger area in the
left atrium.
Anatomic GP ablation used with our approach is not
technically challenging because the locations of the 4 major
atrial GP vary minimally among patients. In the present
study, we elected to ablate the GP according to their anat-
omic locations instead of relying on the parasympathetic
response (hypotension or atrioventricular block) elicited by
HFS. Endocardial HFS at lower voltage often may not elicit
a parasympathetic response, and HFS at higher voltages is
painful and difﬁcult to perform in patients not under general
anesthesia. It is known that both sympathetic and para-
sympathetic elements reside in all 4 major atrial GP (23–25),
as well as the ligament of Marshall (24,25). HFS at sites that
are richly innervated by both the sympathetic and para-
sympathetic neural elements may not elicit a parasympathetic
response at all, and subsequently underestimates the extent of
the GP. Although earlier studies on GP ablation were guided
by the vagal responses elicited by HFS, later studies
demonstrated that the outcome of GP ablation guided byHFS was inferior to that guided by the anatomic locations of
the GP (20). We postulate that GP ablation guided by HFS
underestimates the extent of the major atrial GP and thus
translates into signiﬁcantly less autonomic denervation and
subsequently a lower success rate.
Although inferior to the other 2 approaches, GP ablation
alone still maintained sinus rhythm in 50% patients at 2 years.
In these patients, the PV antra were not isolated, indicating
that autonomic denervation is a major contributor to the efﬁ-
cacy of PVI. It cannot be overemphasized that the conventional
PVI transects the SLGP, ligament of Marshall, ARGP, and
part of the IRGP as well as many small clusters of autonomic
ganglia and nerves. Complete isolation of the PV antra also
eliminates the triggers and substrate in the PV antrum and
ensures that PV ﬁring cannot conduct into the atrium to
initiate AF, rendering a slightly better but not statistically
signiﬁcant outcome compared with GP ablation alone.
We hypothesize that the additional beneﬁt of PVIþGP
ablation may result from a combination of destroying and/
or isolating the triggers of PV ﬁring by PVI, and more
complete autonomic denervation by GP ablation combined
with PVI. Another possibility is that ablation at the GP area
resulted in elimination of the complex electrical activity
located at these parts of the left atrium. Katritsis et al.
(26,27) previously showed that fractionated electrograms are
usually found in the areas of GP. Choi et al. (28) also
identiﬁed intrinsic cardiac nerve activity as a source of
electrogram fractionation and trigger of paroxysmal atrial
tachyarrhythmias including AF, consistent with the possi-
bility that GP ablation may target both autonomic neural
elements and fractionated electrograms.
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2324The PVIþGP approach did not confer a higher risk of
ablation-induced proarrhythmia despite more RF applica-
tions delivered and longer ablation time. Selective GP
modiﬁcation added to PVI has been reported to carry
a higher risk of iatrogenic left atrial tachycardias than PVI
(10). Selective anatomic or HFS-mediated GP ablation was
complicated by atrial macroreentry in 2% to 10% of patients
after ablation, but did not always require a repeat procedure
because these tachycardias may spontaneously resolve with
time (4,11,20,29). In the present study, GP ablation sites
were either on the circumferential PVI lines or were
extended to connect with the circumferential lines to avoid
creating arrhythmogenic channels. This precaution may
account for the lower incidence of left atrial tachycardias
that potentially can be introduced by adding GP ablation
to PVI.
Study limitations. The present study included only
patients with PAF. Although a recent meta-analysis sug-
gested that autonomic denervation plus PVI signiﬁcantly
increase the freedom from recurrence of AF both in
paroxysmal and nonparoxysmal patients (12), the value of
additional ablation (e.g., lines or fractionated electrograms)
to PVI in persistent AF continued to be questioned (30). As
a stand-alone therapy, GP ablation is not enough to confer
a favorable outcome in patients with long-standing persis-
tent AF (29). However, GP ablation alone was still effective
in maintaining sinus rhythm in 38.2% (at 24  3 months)
patients with long-standing persistent AF (29), indicating
that the autonomic nervous system still contributes to the
maintenance of AF in more advanced stages of AF.
Although the efﬁcacy of PVIþGP on patients with persis-
tent/permanent AF is not known, a clinical study to answer
this question is currently under way at our institutions. Our
study entailed selective ablation of the major left atrial GP;
ablation of the crux GP in the left atrium or of the right
atrial GP that might have improved success rates (8) was not
undertaken. The strategy of documentation of any atrial
arrhythmia recurrence certainly has room for improvement.
However, this is a standard approach for post-ablation
assessment according to the 2012 HRS/EHRA/ECAS
Expert Consensus Statement. It is important to point out
that a considerable proportion of patients received ILRs,
and recordings from the ILRs further veriﬁed the docu-
mented the superior efﬁcacy of the PVIþGP approach. In
the last 10 months of follow-up, the success of PVI and GP
ablation continues to decline, but the Kaplan-Meier curve of
the PVIþGP appears to remain ﬂat. Whether PVIþGP will
continue to outperform the other 2 approaches will require
a longer follow-up period, which is ongoing at both centers.
Conclusions
Our data indicate that the outcome of adding anatomic GP
ablation to PVI is better than PVI or GP ablation alone. The
PVIþGP approach is not technically challenging, does not
entail a considerable increase in ﬂuoroscopy time, and can beeasily adopted as a modiﬁcation of conventional PVI by
circumferential ablation.
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